On August 27, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, reported that it participated in the Virtual Investor "Why Now" on-demand conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company’s investment thesis, highlighting why he believes now is a pivotal time for Akari. The discussion highlights the rapidly evolving ADC landscape, increasing industry demand for differentiated payload technologies, and Akari’s proprietary PH1 RNA splicing payload platform, which is designed to address limitations associated with conventional ADC payloads.

The video webcast is now accessible for on-demand viewing here.

JTC Team and Virtual Investor Co. are paid consultants to Akari Therapeutics, Plc. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of Akari Therapeutics, Plc. Interested parties are responsible for conducting their own due diligence and are encouraged to review the Company’s website and the SEC website for the latest information and filings on the Company.

(Press release, Akari Therapeutics, AUG 27, 2026, View Source [SID1234670378])